COMPARE · Reviewed July 29, 2026
AUPH vs EXEL
Verdict: Side-by-side breakdown using the Bull Rankings model. AUPH scored 78.9, EXEL scored 72.6 — AUPH leads.
Compare another set
AUPH
Aurinia Pharmaceuticals Inc.
78.9
$15.18 · $2.0B
fundamentals as of
Score gap
6.3
AUPH leads
EXEL
Exelixis, Inc.
72.6
$55.33 · $13.9B
fundamentals as of
The model, pillar by pillar (0–100 each)
AUPH
stronger →← stronger
EXEL
81
Qualityreturns · margins · balance sheet
96
67
Growthrevenue & earnings expansion
74
91
Valuevaluation vs sector peers
54
EXEL is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
AUPH
EXEL
$167mC
FCF
$918mC+
+20.6%A-
Rev
+3.3%C+
0.12B+
D/E
0.09B+
7.0xA
P/E
18.3xA-
0.34A
PEG
2.56C
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
AUPH
EXEL
21% below
Price vs fair valuelower is cheaper
20% below
~4%/yr
Growth the price implies10-yr FCF · lower = less priced in
~4%/yr
+7%
1-yr DCF upside
+8%
+26%
5-yr DCF upside
+25%
+59%
10-yr DCF upside
+55%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
AUPH
Why this score
- Buying back stock
- Earnings outpace cash
EXEL
Why this score
- Buying back stock
- Durable high returns
The companies
AUPHAurinia Pharmaceuticals Inc.
Why now
Biotechnology · market cap $2.0b. Down 21% from 52-week high of $19.25 — deep drawdown territory. Revenue growing +21%, comfortably above the S&P median. PEG 0.34 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $17.00 (implying +12% upside).
Moat
Net margin 100% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 53% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Beta 1.42 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
EXELExelixis, Inc.
Why now
Biotechnology · market cap $13.9b. 4% off the 52-week high of $57.57. 15 sell-side analysts rate this a Buy with a mean 1-yr target of $52.07 (implying -6% upside).
Moat
Net margin 35% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 43% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 110% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.